2017
Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Tiseo M, Popat S, Gettinger S, Peters S, Haney J, Kerstein D, Camidge D. Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2017, 35: tps9098-tps9098. DOI: 10.1200/jco.2017.35.15_suppl.tps9098.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalObjective response rateRandomized phase 3 trialPhase 3 trialPrimary endpointTKI therapyPositive non-small cell lung cancerAdvanced anaplastic lymphoma kinaseNext-generation ALK inhibitorsRandomized phase 2 trialPrior TKI therapySafety/tolerabilityPhase 1/2 trialPhase 2 trialKaplan-Meier methodCell lung cancerDuration of responseIndependent review committeeLog-rank testPotent preclinical activityTyrosine kinase inhibitorsAnaplastic lymphoma kinaseNaive patientsNSCLC pts
2014
1229PD Smoking History and Response to Nivolumab in Patients with Advanced Nsclcs
Hellmann M, Creelan B, Woo K, Sima C, Iams W, Antonia S, Horn L, Brahmer J, Gettinger S, Harbison C, Rizvi N. 1229PD Smoking History and Response to Nivolumab in Patients with Advanced Nsclcs. Annals Of Oncology 2014, 25: iv429. DOI: 10.1093/annonc/mdu349.8.Peer-Reviewed Original ResearchBristol-Myers SquibbCurrent smokersSmoking historyAdvanced NSCLCResponse rateMutation burdenPD-1 pathway inhibitorsSelf-reported smoking historySubset of ptsHigh somatic mutation burdenLog-rank testSomatic mutation burdenKRAS MUTRECIST v1.0Squamous histologyObjective responseSmoking statusTobacco exposureKRAS genotypeLung cancerMutational burdenSmokersStratification factorsNSCLCNivolumab
2012
Evaluation of the pattern of SOX2 expression in non-small cell lung cancer (NSCLC) and correlation with clinicopathologic (CP) features and prognosis.
Velcheti V, Cheng H, Yao X, Deng Y, Gettinger S, Rimm D. Evaluation of the pattern of SOX2 expression in non-small cell lung cancer (NSCLC) and correlation with clinicopathologic (CP) features and prognosis. Journal Of Clinical Oncology 2012, 30: e21106-e21106. DOI: 10.1200/jco.2012.30.15_suppl.e21106.Peer-Reviewed Original ResearchNon-small cell lung cancerSquamous cell carcinomaSOX2 expressionWorse median overall survivalYale-New Haven HospitalMedian overall survivalMore stage IIIPatras University HospitalKaplan-Meier analysisCell lung cancerLog-rank testHigh SOX2 expressionNew Haven HospitalMore effective markersSOX2 expression levelsOverall survivalCell carcinomaLung cancerUniversity HospitalIndependent cohortKruskal-Wallis testStage IIIBetter outcomesStem cell transcription factorsSurvival analysis